Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 1

Status

Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4Observational 3

Sponsor

Conditions

Myasthenia Gravis 4Recurrence 1Optic Neuritis 1Neuromyelitis Optica 1Myelitis, Transverse 1Demyelinating Diseases 1Adrenal Insufficiency 1

Interventions

rozanolixizumab 10zilucoplan 8efgartigimod alfa 8Rituximab 7Cyclophosphamide 7telitacicept 6fludarabine 6eculizumab 5Prednisone 5ravulizumab 4Pyridostigmine Bromide 4Immunoglobulins, Intravenous 4Hizentra 4Tacrolimus 3Mycophenolic Acid 3HBM9161 3Amifampridine 3thymoglobulin 2inebilizumab 2Prednisolone 2Exercise 2tofacitinib 1tocilizumab 1talquetamab 1satralizumab 1sargramostim 1rhoA GTP-Binding Protein 1remibrutinib 1prednylidene 1iscalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Myasthenia Gravis × ravulizumab × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

NCT05644561 2026-04-17

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
12 enrolled

Myasthenia Gravis

NCT07221838 2026-04-09

OCTAGON

Alexion Pharmaceuticals, Inc.

Phase 4 Recruiting
75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

NCT03920293 2024-05-28

Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
175 enrolled 15 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡